

ARTICLE

Open Access

# Transcriptome profiling analysis reveals that ATP6V0E2 is involved in the lysosomal activation by anlotinib

Xin Sun<sup>1</sup>, Yuhan Shu<sup>2</sup>, Peiyi Yan<sup>3</sup>, Hongliang Huang<sup>4</sup>, Ruilan Gao<sup>5</sup>, Mengting Xu<sup>2</sup>, Liqin Lu<sup>1</sup>, Jingkui Tian<sup>2</sup>, Dongsheng Huang<sup>6</sup> and Jianbin Zhang<sup>1,6</sup>

## Abstract

Anlotinib is a receptor tyrosine kinase inhibitor with potential anti-neoplastic and anti-angiogenic activities. It has been approved for the treatment of non-small-cell lung cancer. Lysosomes are acidic organelles and have been implicated in various mechanisms of cancer therapeutics. However, the effect of anlotinib on lysosomal function has not been investigated. In the present study, anlotinib induces apoptosis in human colon cancer cells. Through transcriptome sequencing, we found for the first time that anlotinib treatment upregulates ATP6V0E2 (ATPase H<sup>+</sup> Transporting V0 Subunit E2) and other lysosome-related genes expression in human colon cancer. In human colon cancer, we validated that anlotinib activates lysosomal function and enhances the fusion of autophagosomes and lysosomes. Moreover, anlotinib treatment is shown to inhibit mTOR (mammalian target of rapamycin) signaling and the activation of lysosomal function by anlotinib is mTOR dependent. Furthermore, anlotinib treatment activates TFEB, a key nuclear transcription factor that controls lysosome biogenesis and function. We found that anlotinib treatment promotes TFEB nuclear translocation and enhances its transcriptional activity. When TFEB or ATP6V0E2 are knocked down, the enhanced lysosomal function and autophagy by anlotinib are attenuated. Finally, inhibition of lysosomal function enhances anlotinib-induced cell death and tumor suppression, which may be attributed to high levels of ROS (reactive oxygen species). These findings suggest that the activation of lysosomal function protects against anlotinib-mediated cell apoptosis via regulating the cellular redox status. Taken together, our results provide novel insights into the regulatory mechanisms of anlotinib on lysosomes, and this information could facilitate the development of potential novel cancer therapeutic agents that inhibit lysosomal function.

## Introduction

Anlotinib, a new oral small-molecule receptor tyrosine kinase inhibitor developed by Chia-tai Tianqing Pharmaceutical Co., Ltd. in China, targets VEGFR1 (vascular

endothelial growth factor receptor 1), VEGFR2, VEGFR3, c-Kit, PDGFR- $\alpha$  (platelet-derived growth factor receptor  $\alpha$ ), FGFR1 (fibroblast growth factor receptor 1), FGFR2, and FGFR3. Through these mechanisms, anlotinib can inhibit tumor angiogenesis and tumor cell proliferation<sup>1,2</sup>. The antitumor effect of anlotinib has been reported in many preclinical and clinical trials<sup>3</sup>. Compared to a placebo, anlotinib improved both progression-free survival and overall survival in a phase III trial in patients with advanced non-small-cell lung cancer<sup>4,5</sup>, despite progression of the cancer after two lines of prior treatments. Recently, anlotinib has been just approved as a third-line treatment for advanced non-small-cell lung cancer patients by the CFDA

Correspondence: Jingkui Tian ([tjk@zju.edu.cn](mailto:tjk@zju.edu.cn)) or Dongsheng Huang ([dshuang@zju.edu.cn](mailto:dshuang@zju.edu.cn)) or Jianbin Zhang ([zhangjianbin@hmc.edu.cn](mailto:zhangjianbin@hmc.edu.cn))

<sup>1</sup>Department of Oncology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China

<sup>2</sup>College of Biomedical Engineering & Instrument Science, Zhejiang University, Hangzhou, China

Full list of author information is available at the end of the article  
These authors contributed equally: Xin Sun, Yuhan Shu, Peiyi Yan  
Edited by N. Barlev

© The Author(s) 2020



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

(China Food and Drug Administration). In addition, a randomized phase IIB trial in patients with advanced soft tissue sarcoma also demonstrates that anlotinib significantly extends the median progression-free survival<sup>6,7</sup>. In patients with advanced medullary thyroid carcinoma and metastatic renal cell carcinoma, anlotinib also shows promising efficacy<sup>8–11</sup>. In human colorectal cancer, the antitumor effect of anlotinib can be enhanced by MiR-940 targeting MACC1's mRNA<sup>12</sup>. Similar to that of other receptor tyrosine kinase inhibitors, the combined treatment of anlotinib with chemotherapy does not appear to be more beneficial than anlotinib alone<sup>13</sup>.

Lysosomes are acidic organelles containing many degradative enzymes. At the late stage of autophagy, autophagosomes fuse with lysosomes and the contents of autophagosomes are degraded by lysosomal enzymes<sup>14,15</sup>. TFEB (transcription factor EB) is one of the most important molecular mechanisms regulating lysosomal function, and it is regulated mainly by its phosphorylation, which is mediated by the mTOR (mammalian target of rapamycin) kinase<sup>16,17</sup>. Our recent study<sup>18</sup> revealed that TFEB is also regulated by another post-translational modification which is acetylation. Lysosomes play important roles in the tumorigenesis<sup>19,20</sup>, such as pancreatic and lung adenocarcinomas, which are characterized with mutant KRAS. The growth and survival of cancer cells in poor microenvironment demand for metabolites, which is achieved by systematically recycling both extracellular and intracellular components via scavenging pathways that converge on the lysosome<sup>21</sup>. Inhibition of lysosomal function can enhance the anti-tumor effect of many drugs<sup>22–24</sup>. Thus, targeting lysosomal function is emerging as a promising strategy in cancer therapeutics.

Compared with other tyrosine kinases, anlotinib occupies the ATP-binding pocket of VEGFR2 tyrosine kinase and shows high selectivity and inhibitory potency<sup>1</sup>. Upon anlotinib treatment, the downstream signaling pathways of VEGFR2 are inhibited, including ERK (extracellular regulated protein kinase) and AKT (protein kinase B) pathways<sup>25</sup>. It has been recently reported that anlotinib is able to induce autophagy, and autophagy inhibition enhances the cytotoxic effects of anlotinib and potentiates the anti-angiogenic property of anlotinib through JAK2 (Janus kinase 2)–STAT3 (signal transducer and activator of transcription 3)–VEGFA signaling<sup>26</sup>. But at the late stage of autophagy, the effect of anlotinib on lysosomal function has still been unknown.

Here, we hypothesize that anlotinib treatment activates lysosomal function and the biological function of lysosome in the anticancer effect of anlotinib is worth investigating. In this study, we found that anlotinib treatment leads to cell apoptosis in human colon cancer. Transcriptome sequencing analysis reveals that

anlotinib targets ATP6V0E2 (ATPase H<sup>+</sup> Transporting V0 Subunit E2) and other lysosome-related genes. We validated that anlotinib treatment activates lysosomal function via inhibiting mTOR signaling and enhancing TFEB transcriptional activity. TFEB or ATP6V0E2 knockdown attenuates anlotinib-induced lysosomal activation, which further enhances the cytotoxicity of anlotinib and leads to more cancer cell apoptosis. Taken together, our data support the notion that combined treatment with anlotinib and lysosomal inhibitors could be a novel promising therapeutic strategy in the treatment of colon cancer.

## Materials and methods

### Cell lines

HCT116 and SW480 cells were obtained from American Type Culture Collection. The GFP-LC3-expressing stable MEF cells, TSC2<sup>+/+</sup> MEFs, TSC2<sup>-/-</sup> MEFs, L929-tfLC3 cells were provided by Prof. Shen Han-Ming (National University of Singapore, Singapore). All cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM) (Sigma-Aldrich, D1152) containing 10% fetal bovine serum (HyClone, SV30160.03) in a 5% CO<sub>2</sub> atmosphere at 37 °C.

### Reagents

Antibodies were obtained as follows: anti-LC3 antibody (Sigma-Aldrich, L7543), anti-tubulin (Sigma-Aldrich, T6199), anti-FLAG (Sigma-Aldrich, F3165), anti-actin (Sigma-Aldrich, A5441), anti-TFEB (Bethyl Laboratories, A303-673A). All of the other antibodies were purchased from Cell Signaling Technology: anti-phospho-AKT (cata. no. 4060), anti-AKT (cata. no. 4691), anti-Bax (cata. no. 2774), anti-Bcl-2 (cata. no. 15071), anti-Cytochrome *c* (cata. no. 4272), anti-Caspase-3 (cata. no. 9662), anti-EGFR (cata. no. 2085), anti-GFP (cata. no. 2955), anti-Ki-67 (cata. no. 9027), anti-LAMP1 (cata. no. 9091S), anti-Lamin A/C (cata. no. 4777), phospho-mTOR (cata. no. 5536), anti-mTOR (cata. no. 2983), anti-phospho-S6 (cata. no. 2211), anti-S6 (cata. no. 2217), anti-PARP-1 (cata. no. 9542), anti-P62 (cata. no. 23214), anti-TSC2 (cata. no. 3612) and anti-14-3-3 (cata. no. 9638).

### Small interfering RNA (siRNA) and transient transfection

The scrambled RNAi oligonucleotides and siRNAs targeting TFEB (sc-38509; Santa Cruz Biotechnology) or ATP6V0E2 (GenePharma, Shanghai) were transfected into HCT116 cells using the Lipofectamine<sup>®</sup> 3000 according to the manufacturer's protocol. After 48 h, the cells were subjected to the designated treatment. For plasmid transfection, cells were transiently transfected with GFP-TFEB or FLAG-TFEB plasmids using the Lipofectamine<sup>®</sup> 2000 according to the manufacturer's protocol. Plasmids were kindly provided by Prof. Shen

Han-Ming (National University of Singapore, Singapore) as described<sup>18,27</sup>.

#### **LysoTracker staining**

After the designated treatments, cells were incubated with 50 nM LysoTracker Red in DMEM for 30 min for labeling and tracking acidic organelles in live cells. The cells in the chambered coverglass were observed under a confocal microscope.

#### **Magic Red cathepsin B and L activity assay**

Lysosomal function was also estimated by the cathepsin B and L enzymatic activity. After designated treatment, cells were further loaded with Magic Red<sup>TM</sup> cathepsin B (Immunochemistry Technologies, 938) or cathepsin L (Immunochemistry Technologies, 942) reagents for 30 min. The cells were collected and the fluorescence intensities of 10,000 cells per sample were measured by flow cytometry. We recorded the fluorescence of Magic Red using the FL-2 channel of FACS (BD Biosciences).

#### **Confocal imaging**

Cells were first cultured on eight-well Lab-Tek<sup>TM</sup> chambered coverglass (Thermo Scientific, 155411) overnight, followed by designated treatment. All of the confocal images were obtained with  $\times 60$  oil objective (numerical aperture 1.4) lenses of Leika TCS SP5 Confocal.

#### **Measurement of ROS production**

CM-H<sub>2</sub>DCFDA (Invitrogen, C6827) was chosen for the detection of intracellular ROS production. After the designated treatments, cells were incubated with 1  $\mu$ M CM-H<sub>2</sub>DCFDA in phosphate-buffered saline (PBS) for 10 min. Then cells were collected and fluorescence intensity was measured. We recorded the fluorescence of CM-DCF using the FL-1 channel of FACS (BD Biosciences).

#### **Western blotting**

After the indicated time of designated treatment, cells were collected and rinsed with PBS. The whole-cell lysates were prepared in the Laemmli buffer (62.5 mM Tris-HCl, pH 6.8, 20% glycerol, 2% sodium dodecyl sulfate (SDS), 2 mM DTT, phosphatase inhibitor, and proteinase inhibitor mixture). An equal amount of protein was resolved by SDS-PAGE and transferred onto PVDF membrane. After blocking with 5% nonfat milk, the membrane was probed with designated first and second antibodies, developed with the enhanced chemiluminescence method (Thermo Scientific, 34076), and visualized using the Bio-Rad ChemiDoc MP Imaging System.

#### **Luciferase assay**

TFEB luciferase vector was provided by Prof. Shen Han-Ming (National University of Singapore). The transient

transfection of the TFEB luciferase vector was done in HCT116 cells using the Lipofectamine<sup>TM</sup> 2000 transfection reagent according to the manufacturer's protocol. Renilla luciferase vector was used as a transfection control. The luciferase activity was measured at 48-h time after transfection using the Dual-Luciferase reporter assay system (Promega, E1960) based on the protocol provided by the manufacturer.

#### **Reverse transcription and quantitative real-time PCR**

RNA was extracted with the RNeasy kit (Qiagen, 217004). A reverse transcription reaction was performed using 1  $\mu$ g of total RNA with iScript<sup>TM</sup> Reverse Transcription Supermix for quantitative reverse transcription PCR (RT-qPCR) (Bio-Rad, 170-8841). The mRNA expression levels were determined by real-time PCR using SsoFast EvaGreen Supermix (Bio-Rad, 172-5201AP) and the CFX96 Touch Real-time PCR Detection System (Bio-Rad). Glyceraldehyde-3-phosphate dehydrogenase was used as an internal control of RNA integrity. Real-time PCR was performed in triplicate.

#### **Transcriptome sequencing**

Total RNA was isolated and purified using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's procedure. The RNA amount and purity of each sample was quantified using NanoDrop ND-1000 (NanoDrop, Wilmington, DE, USA). The RNA integrity was assessed by Agilent 2100 with RIN number  $>7.0$ . Poly (A) RNA is purified from total RNA (5  $\mu$ g) using poly-T oligo-attached magnetic beads using two rounds of purification. Then the poly(A) RNA was fragmented into small pieces using divalent cations under high temperature. Then the cleaved RNA fragments were reverse-transcribed to create the cDNA, which were next used to synthesize U-labeled second-stranded DNAs with *Escherichia coli* DNA polymerase I, RNase H and dUTP. An A-base is then added to the blunt ends of each strand, preparing them for ligation to the indexed adapters. Each adapter contains a T-base overhang for ligating the adapter to the A-tailed fragmented DNA. Single- or dual-index adapters are ligated to the fragments, and size selection was performed with AMPureXP beads. After the heat-labile UDG enzyme treatment of the U-labeled second-stranded DNAs, the ligated products are amplified with PCR by the following conditions: initial denaturation at 95 °C for 3 min; 8 cycles of denaturation at 98 °C for 15 s, annealing at 60 °C for 15 s, and extension at 72 °C for 30 s; and then final extension at 72 °C for 5 min. The average insert size for the final cDNA library was 300 bp ( $\pm 50$  bp). At last, we performed the 150-bp paired-end sequencing on an Illumina X Ten (LC Bio, China) following the vendor's recommended protocol.

### Colony formation assay

HCT116 cells (200 cells) were cultured in six-well plate for 48 h and then treated with different doses of anlotinib. After that, cells were cultured for 12–20 days in culture medium. Surviving colonies were stained with gentian violet after methanol fixation and visible colonies ( $\geq 50$  cells) were counted. The experiments were performed in triplicate.

### Cell proliferation and cytotoxicity assay

Cells were seeded in a 96-well plate and treated with anlotinib in the presence or absence of bafilomycin for 24 h. After treatment, 10  $\mu$ l of CCK-8 (cell counting kit 8, E606335-0500; Sangon Biotech, Shanghai) solution was added to each well of the plate and incubated the plate for 1–4 h in the incubator. Finally, the absorbance at 450 nm was measured using a microplate reader.

### Detection of cell death

Cell death was estimated by morphological changes under phase-contrast microscopy and quantified by Pacific Blue™ Annexin V (A35122, Thermo Fisher Scientific) and PI (propidium iodide, V13244; Thermo Fisher Scientific) staining coupled with flow cytometry (BD Biosciences). Western blotting was also used to indicate the cell death via PARP-1 and Caspase-3 cleavages.

### In vivo xenograft tumor model

Four-week-old male BALB/c nude mice were purchased from the Institute of Zoology, Zhejiang Chinese Medical University. All experiments were performed in accordance with the official recommendations of the Chinese Zoological Society, and animals received humane care according to the criteria outlined in the “Guide for the Care and Use of Laboratory Animals”. A suspension containing  $3 \times 10^6$  HCT116 cells was subcutaneously injected into the right flanks of the nude mice. After 10 days, all mice were randomly divided into four groups: control; anlotinib 50 mg/kg; BAF, 1 mg/kg; anlotinib plus bafilomycin. The tumor dimensions were measured using a Vernier caliper twice per week. Mice were killed 30 days after inoculation, and xenograft tumors were weighed.

### Statistical analysis

All western blotting data and image data presented are representative of three independent experiments. The numeric data except for RT-qPCR data are presented as mean  $\pm$  SD from three independent experiments and analyzed using Student's *t*-test.

## Results

### Anlotinib inhibits cell growth and induces apoptosis in human colon cancer cells

Anti-angiogenesis agents exert their antitumor effect by reducing tumor microvascular density and increasing


tumor hypoxia<sup>28</sup>. We first evaluated the effect of anlotinib on cell growth in human HCT116 and SW480 colon cancer cells. As shown in Supplementary Fig. 1, we observed a significant decrease in both colony size and number with increasing doses. At a concentration of 2.5  $\mu$ M, there was an 80% reduction in colony numbers. Next, we determined cell death changes in anlotinib-treated human colon cancer cells. As shown in Fig. 1a, cell morphology changes showed the shranked, round and low-density cells under anlotinib treatment and more cell death were observed as the doses increased from 1.0 to 10  $\mu$ M, indicating a dose-dependent cytotoxic effect. We next analyzed apoptosis using annexin V and PI staining to quantify apoptotic cells and found that anlotinib significantly induced cell apoptosis at the concentration of 2.5–10  $\mu$ M in HCT116 cells or SW480 cells (Fig. 1b and Supplementary Fig. 2a, b). We also investigated whether anlotinib-induced cell death was associated with treatment time. HCT116 or SW480 cells were treated with anlotinib for different time, and we observed that anlotinib treatment led to more cell apoptosis with the time increased (Supplementary Fig. 2c), suggesting a time-dependent effect. Moreover, our western blotting analysis also revealed that anlotinib increased the expression of the pro-apoptotic proteins, including the cleaved PARP-1 and Caspase-3, Bax and Cytochrome *c*, but decreased the expression of anti-apoptotic protein Bcl-2 (Fig. 1c).

### Identification of ATP6V0E2 as anlotinib target through transcriptome sequencing

To identify potential anlotinib targets, we performed a transcriptome sequencing analysis and screened a large number of genes in human HCT116 cells treated with anlotinib. Compared with the control group, the expression levels of 283 genes were significantly altered following anlotinib treatment. Among these differentially expressed genes, 116 genes were downregulated, and 167 genes were upregulated.

Subsequently, we performed GO (gene ontology) analysis of anlotinib targets. It was shown that these targets are broadly distributed in different parts of the cell, and especially enriched in the nucleus, cytoplasm and plasma membrane (Fig. 2a and Supplementary Table 1). KEGG (kyoto encyclopedia of genes and genomes) analysis showed that anlotinib targets were involved in various signaling pathways, including FoxO (forkhead box), mTOR, AMPK (AMP-activated protein kinase), insulin, Jak–STAT (Janus kinase–signal transducer and activator of transcription), PI3K (phosphoinositide 3-kinase)–AKT, p53, TNF (tumor necrosis factor), VEGF, MAPK (mitogen-activated protein kinase), Ras, Wnt, HIF (hypoxia inducible factor) and so on (Fig. 2b). These signaling pathways were associated with autophagy, lysosome, phagosome, endocytosis, proteolysis, glycolysis, gluconeogenesis, cell cycle,






apoptosis, necroptosis and so on. Among them, the apoptosis and oxidative stress pathways, such as FoxO, p53, TNF and HIF were activated with the upregulation of series of genes, including SERPINE1 (serpin family e member 1), MDM2 (murine double minute 2), GRB2 (growth factor receptor bound protein 2), CREBBP (CREB-binding protein), CREB3L3 (CAMP responsive element-binding protein 3 like 3) and CXCL1 (C-X-C motif chemokine ligand 1). In contrast, the cell proliferation pathways, such as PI3K–AKT, mTOR, AMPK, VEGF, Wnt, MAPK and Ras, were significantly suppressed with the downregulation of series of genes, including ITGA2 (integrin subunit alpha 2), AKT2, AKT1S1 (AKT1 substrate 1), PIK3R2, PIK3R5, WNT2B, WNT4, HNF4A (hepatocyte nuclear factor 4 alpha), CACNA1I (calcium voltage-gated channel subunit alpha1 I), SOCS2 (suppressor of cytokine signaling 2), ENO4 (enolase 4) (Supplementary Fig. 3). It was consistent with the activation of apoptosis and the inhibition of cell growth by anlotinib in human colon cancer (Fig. 1).

It has been well known<sup>16</sup> that the lysosome senses its content and regulates its own biogenesis by a lysosome-

to-nucleus signaling mechanism that involves PI3K–AKT and mTOR signaling pathways. TFEB, a master regulator of lysosomal biogenesis, is phosphorylated by mTOR and transcriptionally regulates lysosome-related genes expression<sup>29</sup>. Our transcriptome sequencing analysis demonstrated that the PI3K–AKT and mTOR signaling pathways were inhibited, which involved CREB3L3, GRB2, ITGA2, ITGB8, MDM2, PIK3R2, PIK3R5, WNT2B and WNT4 genes (Supplementary Fig. 3 and Supplementary Table 2). As a result, the formation of phagosome was enhanced with the upregulation of series of genes, including ATP6V0E2, ATP6V1C2, ATP6V1E2, CTSW (cathepsin W), CTSK (cathepsin K), IRS2 (insulin receptor substrate 2), which were also TFEB target genes.

In the significantly altered genes, 55 upregulated genes and 44 downregulated genes were displayed (Fig. 2c). Among them, ATP6V0E2 was identified as a novel downstream target of anlotinib and also the most significant change (Supplementary Table 3). Here, it was chosen for further study. H<sup>+</sup>-ATPases acidify various intracellular compartments, such as lysosomes. Multiple




**Fig. 2** Anlotinib exerts an inhibitory effect on lysosome-related signaling. HCT116 cells were treated with anlotinib (2.5  $\mu$ M, 12 h) and harvested for RNA extraction. Transcriptome sequencing was performed for human gene expression analysis. **a** GO analysis of cellular localization of the anlotinib targets. **b** KEGG enrichment of signaling pathways in anlotinib-treated cells. The dot represents gene number. **c** Effect of anlotinib on expression of target genes in HCT116 cells. Red and blue represent upregulated and downregulated genes, respectively. The fold changes were shown on the top-right corner.

subunits form  $H^+$ -ATPases, with proteins of the V1 class hydrolyzing ATP for energy to transport  $H^+$ , and proteins of the V0 class forming an integral membrane domain through which  $H^+$  is transported. ATP6V0E2 encodes an isoform of the  $H^+$ -ATPase V0 e subunit, an essential proton pump component<sup>30</sup>. Other  $H^+$ -ATPase subunits were also upregulated by anlotinib, such as ATP6V1C2 and ATP6V1E2 (Supplementary Fig. 3). In addition, the expression levels of cathepsins were also increased, which are ubiquitously expressed lysosomal aspartyl protease and involved in the normal degradation of proteins, including CTSW and CTSK. All of them were required for the formation of phagosome.

### Anlotinib activates lysosomal function in human colon cancer cells


We next sought to examine the effect of anlotinib treatment on the lysosomal function. As shown in Fig. 3a, b, anlotinib significantly increased the formation of GFP-LC3 puncta (a marker of autophagosome formation) in MEFs in a dose-dependent manner. In human colon cancer HCT116 cells, LysoTracker staining showed that lysosomal acidification was significantly increased with following treatment (Fig. 3c, d). Moreover, we determined the autophagy flux level and found that anlotinib treatment further increased LC3-II levels in the presence of BAF (bafilomycin A1) (Fig. 3e and Supplementary Fig. 4),



a known autophagy inhibitor blocking V-ATPase activity. The levels of autophagy substrate P62 were reduced by anlotinib treatment, indicating the increased autophagy flux.

In addition, we treated HCT116 or SW480 cells with anlotinib for different time and observed that the levels of LC3 (autophagosome marker) and LAMP1 (lysosome-associated membrane protein 1) increased over time while P62 levels decreased accordingly (Fig. 3f). EGFR (epidermal growth factor receptor) is known to be degraded

by the lysosome and we measured its changes in abundance in anlotinib-treated cells. As shown in Fig. 3f, anlotinib treatment induced time-dependent EGFR degradation in HCT116 and SW480 cells. Because GFP-LC3 degradation occurs within autolysosomes<sup>31</sup>, we also examined free GFP fragments, which reflect the lysosomal degradation. As shown in Fig. 3g, anlotinib treatment increased the levels of free GFP fragments; in contrast, the levels of GFP-LC3 decreased over time. These results indicate the enhanced lysosomal degradation.



**Fig. 4** Anlotinib activates lysosomal function in a mTOR-dependent manner. **a** HCT116 cells were treated with different doses of anlotinib (1.0, 2.5 or 5  $\mu\text{M}$ , left panel) or treated with anlotinib (2.5  $\mu\text{M}$ ) for different times (6, 12 or 24 h, right panel) as indicated. Cells were harvested and lysed for western blotting to determine phospho-AKT (Ser473) and phospho-S6 (Ser235/236) levels.  $\beta$ -actin was used as a loading control. **b** TSC2<sup>+/+</sup> and TSC2<sup>-/-</sup> MEFs were treated with anlotinib (2.5  $\mu\text{M}$ ) for 12 or 24 h. After the designated treatment, cells were harvested and cell lysates were prepared for western blotting to examine the levels of phospho-mTOR (Ser2448), phospho-AKT (Ser473) and phospho-S6 (Ser235/236). Levels of the autophagy markers LC3-II and P62 were also determined.  $\beta$ -actin was used as a loading control. **c, d** As in **b**, after designated treatment, cells were stained with LysoTracker Red (50 nM, 15 min). Cell fluorescence was measured by confocal microscopy (scale bar: 10  $\mu\text{m}$ ), and quantified by flow cytometry. **e** As in **b**, the treated cells were loaded with Magic Red for cathepsin B or cathepsin L for 15 min. Flow cytometry was performed to determine cell fluorescence, and the values were calculated and statistically analyzed using Student's *t*-test (\* $P$  < 0.05, \*\* $P$  < 0.01, \*\*\* $P$  < 0.001).

During the late stage of autophagy, autophagosomes fuse with lysosomes and are subsequently degraded<sup>27</sup>. Here, we also determined the effect of anlotinib on the fusion of autophagosomes and lysosomes. As shown in Fig. 3h, in MEFs stably expressing GFP-LC3, anlotinib treatment significantly increased the formation of GFP-LC3 puncta in the lysosomes. Moreover, we used L929 cells stably expressing tfLC3 (mRFP-GFP tandem fluorescent-tagged LC3) to examine their fusion<sup>32</sup>. As shown in Fig. 3i, we observed that the RFP-LC3 puncta increased more than the GFP-LC3 puncta following anlotinib treatment. The above findings demonstrate that anlotinib activates lysosomal function by promoting autophosome-lysosome fusion.


#### The activation of lysosome by anlotinib is due to mTOR suppression

One of the most important molecular mechanisms in the regulation of lysosomal function in the course of autophagy

is mTOR signaling<sup>16,27</sup>. Here, we examined the effect of anlotinib on mTOR activity. As shown in Fig. 4a and Supplementary Fig. 5, anlotinib treatment decreased phospho-AKT, -mTOR and -S6 levels in HCT116 or SW480 cells in a time- and dose-dependent manner, indicating the suppression of the AKT-mTOR signaling pathway.

To further establish the role of mTOR in regulating lysosomal function, we utilized TSC2<sup>-/-</sup> MEFs with constitutively active mTOR<sup>33</sup>. Western blotting results showed that the basal activity of mTOR was higher in TSC2<sup>-/-</sup> cells than in TSC2<sup>+/+</sup> cells (Fig. 4b). Anlotinib treatment for 12 h decreased the levels of phospho-mTOR, -AKT and -S6. In TSC2<sup>-/-</sup> cells, however, anlotinib treatment failed to suppress mTOR activity. Consequently, anlotinib induced autophagy in TSC2<sup>+/+</sup> cells as LC3 levels increased and P62 levels decreased over time, but these changes did not occur in TSC2<sup>-/-</sup> cells (Fig. 4b).





LysoTracker and AO (acridine orange) staining show that  $TSC2^{+/+}$  cells had a higher basal level of lysosomal acidification and anlotinib treatment increased the lysosomal acidification to a greater extent in  $TSC2^{+/+}$  cells compared with  $TSC2^{-/-}$  cells (Fig. 4c). Flow cytometry was performed to quantify the changes of cell fluorescence in this set of MEFs and cell fluorescence was significantly increased in  $TSC2^{+/+}$  cells over time under anlotinib treatment (Fig. 4d). When compared with that in  $TSC2^{-/-}$  cells, the increase in cell fluorescence in  $TSC2^{+/+}$  cells was far greater (Fig. 4d). In addition, lysosomal enzyme activity, such as cathepsin B and cathepsin L, was also determined using Magic Red staining. As shown in Fig. 4e, anlotinib treatment led to a more significant increase in cathepsin B and L activity over time in  $TSC2^{+/+}$  cells compared with that in  $TSC2^{-/-}$  cells. These results thus indicate that lysosomal activation by anlotinib is most likely mediated by its suppressive effect on mTOR activity.

#### Anlotinib treatment increases TFEB transcriptional activity

TFEB transcriptionally regulates the expression of autophagy- and lysosomal-related genes and serves as a master regulator for lysosome biogenesis<sup>34</sup>. Here, we measured the transcriptional activity of TFEB in response to anlotinib treatment. In HEK293 cells transiently expressing GFP-TFEB, fluorescence microscopy analysis showed that anlotinib treatment increased the expression levels of TFEB and promoted the translocation of TFEB into the nucleus following 12 h of treatment (Fig. 5a). Consistently, we prepared cellular fractions from anlotinib-treated HCT116 cells and found that more TFEB accumulated in the nucleus after 12 h of anlotinib treatment (Fig. 5b). The translocation of TFEB into the nucleus suggests that the transcriptional activity of TFEB could be enhanced.

Under normal conditions, TFEB colocalizes with the master growth regulator mTOR on the lysosomal membrane and its activity is inhibited<sup>16</sup>. In anlotinib-treated


cells, we previously confirmed that the mTOR signaling is inhibited (Fig. 4a). Thus, we performed an immunoprecipitation assay using FLAG to pull down both FLAG-TFEB and 14-3-3 and found that the interaction of TFEB with 14-3-3 decreased over time (Fig. 5c), suggesting a decrease in phospho-TFEB levels and the post-translational regulation of TFEB.

In addition, a TFEB promoter-driven luciferase reporter was used to measure the transcriptional activity of TFEB. As shown in Fig. 5d, anlotinib treatment significantly increased the luciferase activity of TFEB at the 12-h time point. Finally, we measured the levels of several known targets of TFEB, namely, ATP6V0E2 and CTSB (cathepsin B). In HCT116 cells, the mRNA levels of these genes were significantly increased following anlotinib treatment for

12 h (Fig. 5e). Taken together, these results suggest that anlotinib treatment enhances the transcriptional activity of TFEB and post-translational regulation of TFEB becomes the most important mechanism in lysosomal activation.

#### Knockdown of TFEB or ATP6V0E2 impairs lysosomal activation by anlotinib

We next transiently knocked down TFEB or ATP6V0E2 to validate its regulatory role in anlotinib-mediated lysosomal activation. As shown in Fig. 6a, b, LysoTracker staining showed that TFEB or ATP6V0E2 knockdown decreased cell fluorescence in anlotinib-treated cells. In addition, the anlotinib-induced increase in lysosomal enzyme cathepsin B activity was attenuated by TFEB or ATP6V0E2 knockdown (Fig. 6c, d). Consistent with these




result, the lysosomal degradation of EGFR induced by anlotinib was blocked in ATP6V0E2 or TFEB knockdown cells (Fig. 6e, f). Moreover, ATP6V0E2 or TFEB knockdown decreased autophagy levels in anlotinib-treated cells with little increase in LC3 levels or decrease in P62 levels (Fig. 6e, f). These results indicate that ATP6V0E2 and TFEB are required for anlotinib-induced lysosomal activation and autophagy induction.

### Lysosomal activation protects against cell apoptosis induced by anlotinib

Next, we sought to examine the functional role of lysosomal activation in anlotinib-induced cytotoxicity. We knocked down TFEB or ATP6V0E2 expression in HCT116 cells and treated the cells with anlotinib. As shown in Fig. 7a, b, changes in cell morphology indicated that anlotinib treatment caused more cell death in TFEB or ATP6V0E2 knockdown cells. Next, we quantified the cell apoptosis

using annexin V and PI staining<sup>35</sup>. The results showed that TFEB or ATP6V0E2 knockdown led to a significant increase in cell apoptosis upon anlotinib treatment (Fig. 7c, d and Supplementary Fig. 6). Consistently, western blotting results showed that the cleavage of Caspase-3 or PARP-1 representing cell apoptosis was markedly increased by anlotinib upon TFEB or ATP6V0E2 knockdown (Fig. 7e, f). The above findings demonstrate that lysosomal activation protects against anlotinib-induced cell apoptosis.


To further elucidate the link between lysosomal inhibition and cell apoptosis by anlotinib, we measured the changes in ROS levels in anlotinib-treated cells using a CM-H<sub>2</sub>DCFDA probe<sup>36</sup>. As shown in Fig. 7g, h, ATP6V0E2 knockdown significantly increased ROS levels in anlotinib-treated cells, and this increase may result in more cell death. These findings demonstrate that the lysosome protects against cell death by regulating the cellular redox status.



### Lysosomal inhibition enhances the tumor suppression by anlotinib

Finally, we determined the lysosomal function in anti-tumor effect by anlotinib. We used lysosomal inhibitor BAF to determine the functional role of lysosome in anlotinib-induced cell death through blocking V-ATPase activity. Cell morphology changes also showed that anlotinib treatment induced more cell death under lysosomal inhibition (Fig. 8a). Consistently, autophagy inhibition significantly increased annexin V staining and the cleavages of caspase-3 and PARP-1 (Fig. 8b, c). These observations thus indicate that anlotinib-activated lysosomal function promotes cell survival.

Based on the above results, xenograft models were used to further confirm the effect of anlotinib-mediated autophagy and apoptosis on tumor growth in vivo. After HCT116 cells were injected subcutaneously into their right flanks, nude mice were divided into four groups. As shown in Fig. 8d, 10 days after inoculation, tumor-bearing mice were given an intratumoral injection of anlotinib with or without BAF, an inhibitor of vacuolar type H<sup>+</sup>-ATPase. No significant differences in tumor suppression were observed between the BAF-treated group and the PBS-treated control group. However, anlotinib treatment with or without BAF led to a significant tumor suppression in all nude mice (Fig. 8d). Moreover,



**Fig. 8 Inhibition of lysosomal function enhances the therapeutic efficacy of anlotinib.** HCT116 cells were treated with anlotinib (5.0  $\mu$ M, 24 h) in the presence of lysosomal inhibitor BAF (10 nM). **a** Cell morphology changes were captured with an inverted microscope (scale bar: 100  $\mu$ m, up panel). **b** The treated cells were stained with Annexin V-Pacific blue and cell fluorescence was quantified by flow cytometry. The data are presented as the mean  $\pm$  SD (\* $P$  < 0.05, \*\* $P$  < 0.01). **c** The treated cells were harvested and lysed for western blotting to measure the levels of cleaved PARP-1 and Caspase-3. Inhibition of tumor growth in vivo by anlotinib and BAF. **d** Xenograft tumor volumes were measured twice per week and then quantified and statistically analyzed. Anlotinib plus BAF had a more significant antitumor effect than anlotinib treatment alone; BAF alone treatment had little antitumor effect (\* $P$  < 0.05, \*\* $P$  < 0.01). **e** Typical images of the tumor-bearing mice with their xenograft tumors. **f** The average tumor weight for each group was calculated and statistically analyzed (\* $P$  < 0.05). **g** Representative images of IHC staining of Ki-67 and LC3 were performed on serial sections of tumors from various groups. **h** A schematic model of the activation of lysosomal function by anlotinib in human colon cancer.



compared to treatment with anlotinib alone, the combined treatment with anlotinib and BAF significantly suppressed tumor growth. At 21 days after inoculation, all mice were sacrificed and tumor was removed from mice. As expected, the tumor weight in the BAF treatment did not show a significant difference compared with those in the PBS control group (Fig. 8e, f). The combined treatment with anlotinib and BAF group exerted greater antitumor effect in HCT116 xenograft tumor models compared with the drugs administered independently. Moreover, the expressions of Ki-67 and LC3 in xenografts were detected by immunohistochemistry. Compared with any other group, the expressions of Ki-67 was significantly reduced in the combined treatment group (Fig. 8g), suggesting a lower proliferation rate. Accompaniedly, the levels of LC3 were significantly increased in the combined treatment group. These results indicate that lysosomal inhibition could enhance the anticancer effect of anlotinib *in vivo*.

## Discussion

Despite continued attempts to develop therapeutic and screening methods, colon cancer remains a major life-threatening malignancy. The common treatment is standard chemotherapy and targeted therapy followed by complete surgical resection<sup>37</sup>. Anlotinib is a novel oral multi-targeted receptor tyrosine kinase inhibitor that was synthesized to primarily inhibit a group of newly identified kinases<sup>3</sup>. In the present study, we sought to investigate the relationship between the lysosome and the therapeutic response to anlotinib in human colon cancer and further explore its possible mechanism, in an attempt to provide clinical therapy choices for colon cancer patients. Our findings demonstrate that the inhibition of lysosomal function can enhance the cytotoxicity of anlotinib in human colon cancer.

Previous studies showed that anti-angiogenesis agents can reduce tumor microvascular density and increase tumor hypoxia, leading to autophagy activation in tumor cells<sup>38</sup>. Here, in human colon cancer cells, we observed for the first time that autophagy flux is enhanced by anlotinib treatment, as indicated by an increase in LC3 (autophagosome marker) and a decrease in P62 (autophagy substrate) (Fig. 3a, b, e). Moreover, lysosomal functions are activated by anlotinib treatment, as evidenced by (i) an increase in lysosomal acidification (reduced lysosomal pH) (Fig. 3c, d); (ii) enhanced lysosomal cathepsin B and L activity (Fig. 4e); and (iii) increased lysosomal degradative activity EGFR degradation and GFP-LC3 cleavage (Fig. 3f, g). At the same time, we observed that cell apoptosis was also induced in anlotinib-treated cells with increasing time and dosage (Fig. 1). Recent studies suggest that the autophagy and apoptosis signaling pathways interact with each other<sup>39–41</sup>. The inhibition of autophagy function can

enhance apoptosis in cancer cells<sup>22,40</sup> but autophagy can also promote apoptosis in an inflammatory microenvironment<sup>42</sup>. In our present study, we demonstrated that adding lysosomal inhibitors such as BAF to block autophagy induces more cell growth inhibition and apoptosis induction by anlotinib (Fig. 8a–c). Although the function of autophagy induced by anti-angiogenesis agents remains ambiguous, it is considered to play a cytoprotective role in most cases.

At the late stage of autophagy, autophagosomes fuse with lysosomes and their contents are then degraded by the lysosomes<sup>43</sup>. We also determined the effect of anlotinib on this process and observed that anlotinib treatment enhances their fusions (Fig. 3h, i). It has been reported<sup>27</sup> that the fusion of autophagosomes with lysosomes contributes to lysosomal activation, and we confirmed the positive effect of anlotinib on lysosomal function (Fig. 3). Due to mTOR suppression, the phosphorylation levels of TFEB was decreased accordingly (Fig. 5) and the post-translational regulation of TFEB became the most important mechanism regulating lysosomal function in anlotinib-treated cells. On the one hand, the lower phosphorylation levels of TFEB enhanced the transcriptional activity of TFEB<sup>16,44</sup>; on the other hand, the inhibition of the TFEB phosphorylation decreased its degradation and thus increased its expression levels (Fig. 5a)<sup>45</sup>. In the regulation of lysosomal function, a large number of lysosome-related genes were upregulated by anlotinib and ATP6V0E2 was first identified as a key target of anlotinib using transcriptome sequencing (Fig. 2c). It is one target of TFEB and transcriptionally regulated by the latter, which is the master regulator controlling lysosome biogenesis<sup>17,34</sup>. When ATP6V0E2 was knocked down, lysosomal activation was impaired in anlotinib-treated cells (Fig. 6), confirming its important function in lysosomal activation.

More recently<sup>46,47</sup>, lysosomes have been revealed to participate in tumor invasion, angiogenesis, metastasis and even some aspects of antiangiogenic drug resistance. It satisfies the demand for metabolites by cancer cells and protects their survival in poor microenvironment through lysosomal degradation of cellular components<sup>21</sup>. In our study, when lysosomal functions were inhibited either by TFEB or ATP6V0E2 knockdown, anlotinib treatment increased cancer cell death (Figs. 7 and 8). Moreover, *in vivo* xenograft models of colon cancer showed that lysosomal inhibition by BAF enhances the tumor suppressive properties of anlotinib (Fig. 8d–f), suggesting that the lysosome serves to promote cell survival. Our results support the notion that anlotinib and lysosomal inhibition can function as a combined therapeutic strategy for enhanced antitumor therapy.

In the transcriptome sequencing, other targets related with apoptosis and oxidative stress pathways were also upregulated by anlotinib (Fig. 2c). The downstream

targets of p53, CREBBP binds to CREB protein and involves in the transcriptional coactivation of many transcription factors<sup>48</sup>. Among its related pathways are direct p53 effectors<sup>49</sup>. Under oxidative stress by anlotinib, hypoxia increased the expression of SERPINE1 (ref. <sup>50</sup>), one downstream target of HIF. Meanwhile, FOS proteins FOSB and FOSL1 (FOS like 1) also mediate transcriptional responses to oxidative stress by dimerizing with proteins of the JUN family to form AP-1 (activator protein 1) complex<sup>51,52</sup>. On the contrary, other targets involved in cell proliferation, protein trafficking and energy metabolism were downregulated (Fig. 2c). AKT1S1 (AKT1 substrate 1), a proline-rich substrate of AKT that binds 14-3-3 protein when phosphorylated<sup>53</sup>, regulating cell growth and survival, was downregulated under anlotinib treatment. The levels of several targets for protein trafficking were also decreased. SLC29A1 (solute carrier family 29 member 1), a transmembrane glycoprotein, serves as nucleoside transporters<sup>54</sup>. Vps25 (vacuolar protein sorting 25 homolog) and Vps72 (vacuolar protein sorting 72 homolog) play a role in vesicle-mediated protein trafficking<sup>55,56</sup>. Flot2 (Flotillin 2) is a caveolae-associated, integral membrane protein involved in vesicular trafficking and signal transduction<sup>57</sup>. Meanwhile, a series of targets, which encode mitochondrial enzyme and involve in energy metabolism, were also significantly downregulated and failed to protect cells against oxidative damage. GPX1 (glutathione peroxidase 1) catalyzes the reduction of organic hydroperoxides and hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) by glutathione<sup>58</sup>. GPD1L (glycerol-3-phosphate dehydrogenase 1 like) plays a critical role in carbohydrate and lipid metabolism<sup>59</sup>. ALDH3B1 (aldehyde dehydrogenase) enzymes are critical in the detoxification of aldehydes<sup>60</sup>. In addition, the levels of genes encoding mitochondrial membrane protein to maintain membrane integrity were also decreased. TIMM10 (translocase of inner mitochondrial membrane 10) is an essential protein of the mitochondrial intermembrane space<sup>61</sup>. FIS1 (fission, mitochondrial 1) regulates mitochondrial morphology<sup>62</sup>. The above results indicated that under anlotinib treatment, cells growth and metabolism slow down and demonstrate more stress responses. Thus, we speculate that anlotinib may exert its biological function through various different pathways.

Taken together, our findings demonstrate a novel mechanism of the anticancer drug anlotinib in human colon cancer in which lysosomal function is activated to protect against cell apoptosis (Fig. 8h). Thus, the inhibition of lysosomal function can be developed as a novel method to increase the cytotoxicity of anlotinib.

#### Acknowledgements

This work was supported by research grants from Zhejiang Provincial Natural Science Foundation of China (LR18H160002), National Natural Science Foundation of China (31701199), Traditional Chinese Medicine Scientific

Research Fund Project of Zhejiang Province (2018ZB010), Zhejiang Provincial Program in Medicine and Health Sciences and Technology (2018253645), Zhejiang Provincial Outstanding Talent Project of Ten Thousand Talents Program, Zhejiang Provincial Qianjiang Talents Program to Z.J. and National Natural Science Foundation of China (81703907) to S.X.

#### Author details

<sup>1</sup>Department of Oncology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China. <sup>2</sup>College of Biomedical Engineering & Instrument Science, Zhejiang University, Hangzhou, China. <sup>3</sup>Department of Clinical Laboratory, Shanghai Putuo District People's Hospital, Shanghai, China. <sup>4</sup>School of Biosciences & Biopharmaceutics and Center for Bioresources & Drug Discovery, Guangdong Pharmaceutical University, Guangzhou, China. <sup>5</sup>Institution of Hematology Research, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China. <sup>6</sup>Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Clinical Research Institute, People's Hospital of Hangzhou Medical College, Hangzhou, China

#### Conflict of interest

The authors declare that they have no conflict of interest.

#### Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Supplementary Information** accompanies this paper at (<https://doi.org/10.1038/s41419-020-02904-0>).

Received: 13 October 2019 Revised: 6 August 2020 Accepted: 7 August 2020

Published online: 24 August 2020

#### References

- Xie, C. et al. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. *Cancer Sci.* **109**, 1207–1219 (2018).
- Taurin, S. et al. Abstract 3244: treatment of endometrial cancer cells with a new small tyrosine kinase inhibitor targeting mutated fibroblast growth factor receptor-2. *Cancer Res.* **77**(Suppl.), 3244 (2017).
- Shen, G. et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. *J. Hematol. Oncol.* **11**, 120 (2018).
- Han, B. et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). *Br. J. Cancer* **118**, 654–661 (2018).
- Han, B. et al. Third-line treatment: a randomized, double-blind, placebo-controlled phase III ALTER-0303 study-efficacy and safety of anlotinib treatment in patients with refractory advanced NSCLC. *J. Clin. Oncol.* **35**(Suppl), 9053 (2017).
- Chi, Y. et al. Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma. *Clin. Cancer Res.* **24**, 5233–5238 (2018).
- Chi, Y. et al. Anlotinib for metastasis soft tissue sarcoma: a randomized, double-blind, placebo controlled and multi-centered clinical trial. *J. Clin. Oncol.* **36**(Suppl), 11503 (2018).
- Ruan, X. et al. Antitumor effects of anlotinib in thyroid cancer. *Endocr. Relat. Cancer* **26**, 153–164 (2019).
- Zhou, A. P. et al. Anlotinib in metastatic renal cell carcinoma (mRCC) with a previous anti-VEGFR TKI: preliminary results from a multicenter, phase II trial. *J. Clin. Oncol.* **34**(Suppl), e16082 (2016).
- Sun, Y. et al. Phase II study of anlotinib for treatment of advanced medullary thyroid carcinoma. *J. Clin. Oncol.* **34**(Suppl.), 6015 (2016).
- Zhou, A. P. et al. Anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma: a randomized phase II clinical trial. *Oncologist* **24**, e702–e708 (2019).
- Wang, Y. et al. MicroRNA-940 restricts the expression of metastasis-associated gene MACC1 and enhances the antitumor effect of Anlotinib on colorectal cancer. *Onco Targets Ther.* **12**, 2809–2822 (2019).

13. Su, Y. et al. A case report of advanced lung adenocarcinoma harboring KRAS mutation treated with anlotinib. *Zhongguo Fei Ai Za Zhi* **21**, 428–430 (2018).
14. Settembre, C., Fraldi, A., Medina, D. L. & Ballabio, A. Signals from the lysosome: a control centre for cellular clearance and energy metabolism. *Nat. Rev. Mol. Cell Biol.* **14**, 283–296 (2013).
15. Eskelinen, E. L. & Saftig, P. Autophagy: a lysosomal degradation pathway with a central role in health and disease. *Biochim. Biophys. Acta* **1793**, 664–673 (2009).
16. Settembre, C. et al. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. *EMBO J.* **31**, 1095–1108 (2012).
17. Sardiello, M. et al. A gene network regulating lysosomal biogenesis and function. *Science* **325**, 473–477 (2009).
18. Zhang, J. et al. Importance of TFEB acetylation in control of its transcriptional activity and lysosomal function in response to histone deacetylase inhibitors. *Autophagy* **14**, 1043–1059 (2018).
19. Hamalisto, S. & Jaattela, M. Lysosomes in cancer—living on the edge (of the cell). *Curr. Opin. Cell Biol.* **39**, 69–76 (2016).
20. Commisso, C. et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. *Nature* **497**, 633–637 (2013).
21. Guo, J. Y. et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. *Genes Dev.* **25**, 460–470 (2011).
22. Zhang, J. et al. Docetaxel enhances lysosomal function through TFEB activation. *Cell Death Dis.* **9**, 614 (2018).
23. Zhang, J. et al. Curcumin targets the TFEB-lysosome pathway for induction of autophagy. *Oncotarget* **7**, 75659–75671 (2016).
24. Zhang, J. et al. Histone deacetylase inhibitors induce autophagy through FOXO1-dependent pathways. *Autophagy* **11**, 629–642 (2015).
25. Si, X. et al. Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer. *Lung Cancer* **122**, 32–37 (2018).
26. Liang, L. et al. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells. *J. Exp. Clin. Cancer Res.* **38**, 71 (2019).
27. Zhou, J. et al. Activation of lysosomal function in the course of autophagy via mTORC1 suppression and autophagosome-lysosome fusion. *Cell Res.* **23**, 508–523 (2013).
28. Folkman, J. Tumor angiogenesis: therapeutic implications. *N. Engl. J. Med.* **285**, 1182–1186 (1971).
29. Rocznik-Ferguson, A. et al. The transcription factor TFEB links mTORC1 signaling to transcriptional control of lysosome homeostasis. *Sci. Signal.* **5**, ra42 (2012).
30. Blake-Palmer, K. G., Su, Y., Smith, A. N. & Karet, F. E. Molecular cloning and characterization of a novel form of the human vacuolar H<sup>+</sup>-ATPase e-subunit: an essential proton pump component. *Gene* **393**, 94–100 (2007).
31. Ni, H. M. et al. Dissecting the dynamic turnover of GFP-LC3 in the autolysosome. *Autophagy* **7**, 188–204 (2011).
32. Kimura, S., Noda, T. & Yoshimori, T. Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. *Autophagy* **3**, 452–460 (2007).
33. Kwiatkowski, D. J. Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis. *Cancer Biol. Ther.* **2**, 471–476 (2003).
34. Settembre, C. & Ballabio, A. TFEB regulates autophagy: an integrated coordination of cellular degradation and recycling processes. *Autophagy* **7**, 1379–1381 (2011).
35. Meers, P. & Mealy, T. Phospholipid determinants for annexin V binding sites and the role of tryptophan 187. *Biochemistry* **33**, 5829–5837 (1994).
36. Li, X. et al. Hypericin-mediated sonodynamic therapy induces autophagy and decreases lipids in THP-1 macrophage by promoting ROS-dependent nuclear translocation of TFEB. *Cell Death Dis.* **7**, e2527 (2016).
37. Cespedes Feliciano, E. M. et al. Metabolic dysfunction, obesity, and survival among patients with early-stage colorectal cancer. *J. Clin. Oncol.* **34**, 3664–3671 (2016).
38. Liu, J., Fan, L., Wang, H. & Sun, G. Autophagy, a double-edged sword in anti-angiogenesis therapy. *Med. Oncol.* **33**, 10 (2016).
39. Gump, J. M. & Thorburn, A. Autophagy and apoptosis: what is the connection? *Trends Cell Biol.* **21**, 387–392 (2011).
40. Singh, S. S. et al. Dual role of autophagy in hallmarks of cancer. *Oncogene* **37**, 1142–1158 (2018).
41. Ryter, S. W., Mizumura, K. & Choi, A. M. The impact of autophagy on cell death modalities. *Int. J. Cell Biol.* **2014**, 502676 (2014).
42. Dang, S. et al. Autophagy promotes apoptosis of mesenchymal stem cells under inflammatory microenvironment. *Stem Cell Res. Ther.* **6**, 247 (2015).
43. Zhou, J., Tan, S. H., Codogno, P. & Shen, H. M. Dual suppressive effect of mTORC1 on autophagy: tame the dragon by shackling both the head and the tail. *Autophagy* **9**, 803–805 (2013).
44. Yan, P. et al. The polyphenolic compound curcumin conjugation with an alkyne moiety in the process of autophagy. *Am. J. Chin. Med.* **46**, 673–687 (2018).
45. Sha, Y. et al. STUB1 regulates TFEB-induced autophagy-lysosome pathway. *EMBO J.* **36**, 2544–2552 (2017).
46. Zhitomirsky, B. & Assaraf, Y. G. Lysosomal accumulation of anticancer drugs triggers lysosomal exocytosis. *Oncotarget* **8**, 45117–45132 (2017).
47. Zhitomirsky, B. & Assaraf, Y. G. Lysosomes as mediators of drug resistance in cancer. *Drug Resist. Update* **24**, 23–33 (2016).
48. Kwok, R. P. et al. Nuclear protein CBP is a coactivator for the transcription factor CREB. *Nature* **370**, 223–226 (1994).
49. Gu, W., Shi, X. L. & Roeder, R. G. Synergistic activation of transcription by CBP and p53. *Nature* **387**, 819–823 (1997).
50. Azimi, I., Petersen, R. M., Thompson, E. W., Roberts-Thomson, S. J. & Monteith, G. R. Hypoxia-induced reactive oxygen species mediate N-cadherin and SERPINE1 expression, EGFR signalling and motility in MDA-MB-468 breast cancer cells. *Sci. Rep.* **7**, 15140 (2017).
51. Maki, A., Berezsky, I. K., Fargnoli, J., Holbrook, N. J. & Trump, B. F. Role of [Ca<sup>2+</sup>]<sub>i</sub> in induction of c-fos, c-jun, and c-myc mRNA in rat PTE after oxidative stress. *FASEB J.* **6**, 919–924 (1992).
52. Karin, M., Liu, Z. & Zandi, E. AP-1 function and regulation. *Curr. Opin. Cell Biol.* **9**, 240–246 (1997).
53. He, C. L. et al. Pyruvate kinase M2 activates mTORC1 by phosphorylating AKT1S1. *Sci. Rep.* **6**, 21524 (2016).
54. Coe, I. R., Griffiths, M., Young, J. D., Baldwin, S. A. & Cass, C. E. Assignment of the human equilibrative nucleoside transporter (hENT1) to 6p21.1-p21.2. *Genomics* **45**, 459–460 (1997).
55. Slater, R. & Bishop, N. E. Genetic structure and evolution of the Vps25 family, a yeast ESCRT-II component. *BMC Evol. Biol.* **6**, 59 (2006).
56. Horikawa, I., Tanaka, H., Yuasa, Y., Suzuki, M. & Oshimura, M. Molecular cloning of a novel human cDNA on chromosome 1q21 and its mouse homolog encoding a nuclear protein with DNA-binding ability. *Biochem. Biophys. Res. Commun.* **208**, 999–1007 (1995).
57. Bodrikov, V., Pauschert, A., Kochlamazashvili, G. & Stuermer, C. A. O. Reggie-1 and reggie-2 (flotillins) participate in Rab11a-dependent cargo trafficking, spine synapse formation and LTP-related AMPA receptor (GluA1) surface exposure in mouse hippocampal neurons. *Exp. Neurol.* **289**, 31–45 (2017).
58. Brigelius-Flohe, R. & Maiorino, M. Glutathione peroxidases. *Biochim. Biophys. Acta* **1830**, 3289–3303 (2013).
59. Valdivia, C. R., Ueda, K., Ackerman, M. J. & Makielski, J. C. GPD1L links redox state to cardiac excitability by PKC-dependent phosphorylation of the sodium channel SCN5A. *Am. J. Physiol. Heart. Circ. Physiol.* **297**, H1446–H1452 (2009).
60. Marchitti, S. A., Orlicky, D. J. & Vasilou, V. Expression and initial characterization of human ALDH3B1. *Biochem. Biophys. Res. Commun.* **356**, 792–798 (2007).
61. Koehler, C. M. et al. Import of mitochondrial carriers mediated by essential proteins of the intermembrane space. *Science* **279**, 369–373 (1998).
62. Yu, R., Jin, S. B., Lendahl, U., Nister, M. & Zhao, J. Human Fis1 regulates mitochondria dynamics through inhibition of the fusion machinery. *EMBO J.* **38**, e99748 (2019).